Is There Any Advantage of Using Polyclonal vs. Monoclonal Antibodies for Passive Enhancement of Immunity in Patients with COVID-19?
Main Article Content
Keywords
COVID-19, SARS-CoV-2, Monoclonal Antibodies, Polyclonal Antibodies, Bamlanivimab, Etesevimab, Casirivimab, Imdevimab, Sotrovimab, SAB-185, FDA
Abstract
N/A
References
1. Emergency Use Authorization (EUA) for bamlanivimab 700mg IV Center for Drug Evaluation and Research (CDER) Review. 2020. https://www.fda.gov/media/144118/download (Accessed October 26, 2021).
2. Emergency Use Authorization for REGEN-COV for the treatment of mild-moderate COVID-19. 2020. https://www.fda.gov/media/145610/download . (Accessed October 26, 2021).
3. FDA Revokes Initial Emergency Use Authorization of Monotherapy with Bamlanivimab. March 2021. https://www.fda.gov/media/143602/download (Accessed October 27, 2021).
4. FDA Authorizes Additional Monoclonal Antibody for Treatment of COVID-19. 2021. https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-additional-monoclonal-antibody-treatment-covid-19 . (Accessed October 27, 2021).
5. Giovagnoli A. (2021). The Bayesian Design of Adaptive Clinical Trials. International journal of environmental research and public health, 18(2), 530. https://doi.org/10.3390/ijerph18020530
6. Gilliland T, Liu Y, Li R, Dunn M, Cottle E, Terada Y, Rickman Z, Alcorn M, Vasilatos S, Lundy J, Larson D, Wu H, Luke T, Bausch C, Egland K, Sullivan E, Wang Z, Klimstra WB. Protection of human ACE2 transgenic Syrian hamsters from SARS CoV-2 variants by human polyclonal IgG from hyper-immunized transchromosomic bovines. bioRxiv [Preprint]. 2021 Jul 26:2021.07.26.453840. doi: 10.1101/2021.07.26.453840. PMID: 34341790; PMCID: PMC8328057.
7. Liu Z, Wu H, Egland KA, Gilliland TC, Dunn MD, Luke TC, Sullivan EJ, Klimstra WB, Bausch CL, Whelan SPJ. Human immunoglobulin from transchromosomic bovines hyperimmunized with SARS-CoV-2 spike antigen efficiently neutralizes viral variants. Hum Vaccin Immunother. 2021 Jul 6:1-10. doi:10.1080/21645515.2021.1940652. Epub ahead of print. PMID: 34228597; PMCID: PMC8290372.
2. Emergency Use Authorization for REGEN-COV for the treatment of mild-moderate COVID-19. 2020. https://www.fda.gov/media/145610/download . (Accessed October 26, 2021).
3. FDA Revokes Initial Emergency Use Authorization of Monotherapy with Bamlanivimab. March 2021. https://www.fda.gov/media/143602/download (Accessed October 27, 2021).
4. FDA Authorizes Additional Monoclonal Antibody for Treatment of COVID-19. 2021. https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-additional-monoclonal-antibody-treatment-covid-19 . (Accessed October 27, 2021).
5. Giovagnoli A. (2021). The Bayesian Design of Adaptive Clinical Trials. International journal of environmental research and public health, 18(2), 530. https://doi.org/10.3390/ijerph18020530
6. Gilliland T, Liu Y, Li R, Dunn M, Cottle E, Terada Y, Rickman Z, Alcorn M, Vasilatos S, Lundy J, Larson D, Wu H, Luke T, Bausch C, Egland K, Sullivan E, Wang Z, Klimstra WB. Protection of human ACE2 transgenic Syrian hamsters from SARS CoV-2 variants by human polyclonal IgG from hyper-immunized transchromosomic bovines. bioRxiv [Preprint]. 2021 Jul 26:2021.07.26.453840. doi: 10.1101/2021.07.26.453840. PMID: 34341790; PMCID: PMC8328057.
7. Liu Z, Wu H, Egland KA, Gilliland TC, Dunn MD, Luke TC, Sullivan EJ, Klimstra WB, Bausch CL, Whelan SPJ. Human immunoglobulin from transchromosomic bovines hyperimmunized with SARS-CoV-2 spike antigen efficiently neutralizes viral variants. Hum Vaccin Immunother. 2021 Jul 6:1-10. doi:10.1080/21645515.2021.1940652. Epub ahead of print. PMID: 34228597; PMCID: PMC8290372.